First sofosbuvir active pharmaceutical ingredient (API) prequalified
Sofosbuvir (WHOAPI-290) manufactured by
Sofosbuvir (WHOAPI-290) manufactured by
The Prequalification Team is publishing a request for proposals for consultancy services relating to - developing and maintaining the Quality Management Systems (QMS) and assuming the responsibilit
Applicants and Contract Research Organizations (CROs) performing bioequivalence studies are reminded that all studies with human subjects must be conducted in compliance with Good Clinical Practice
TB336: Rifapentine - 150mg - Film-coated tablets - Sanofi-Aventis U.S. LLC - USA
Miltefosine 10mg and 50mg capsule
The revisions to the BTIF (Bioequivalence Trial Information Form) include the following changes to facilitate study assessment:
The 11th invitation to manufacturers of active pharmaceutical ingredients (APIs) to submit an expression of interest (EOI) for API prequalification to the WHO Prequalification Team: medicines (PQTm
WHO Prequalification Unit (PQT) added the below new product to its prequalified list: